ADVERTISEMENT
 
 

Misonix, Inc. to Report Second Quarter Fiscal 2012 Financial Results on Wednesday, February 8, 2012

Conference call to be conducted at 4:30 pm ET
Related Research You May Be Interested In
WEIGHING FOR EFFECT or PLANNING FOR SHRINKAGE
Food manufacturers of powder-based products must consider both weight and volume when packaging their goods. Use of a weight measurement ensures that each package provides the guaranteed portion due ...Read More
Food manufacturers of powder-based products must consider both weight and volume when packaging their goods. Use of a weight measurement ensures that each package provides the guaranteed portion due the customer. Volume of the product during the fill process, however, is oftentimes greater than the perceived amount in the bag once in the customer’s hands. This is due to consolidation of the powder which takes place in the intervening time period.

How do manufacturers know what this shrinkage factor will be? And will it cause a problem for the customer if they think that they are being cheated?
The Science Behind Smart Outsourcing: Four Steps to Success
During uncertain times, knowing when and if outsourcing laboratory services makes sense is critical – especially to your bottom line. This white paper focuses
on the steps companies should follow for ...Read More
During uncertain times, knowing when and if outsourcing laboratory services makes sense is critical – especially to your bottom line. This white paper focuses
on the steps companies should follow for deciding whether or not outsourcing is the best option, how to properly evaluate funding an in-house laboratory, and how to use the Celsis Workload Assessment Model to proactively manage labor cost decisions.

More and more companies are looking at outsourcing laboratory services as a business strategy to drive cost savings. An array of services can be outsourced in the pharmaceutical and biopharmaceutical industries. These include research and laboratory testing as well as manufacturing.

In this white paper, we’ll focus on how to evaluate the costs and benefits of outsourcing lab services -- a key competitive differentiator and a way for companies to deliver greater value to their customers.

By: Celsis Analytical Services | Published: 3/1/2011

Companies Mentioned in this Press Release:

Business Categories Mentioned in this Press Release:

 

FARMINGDALE, N.Y., Feb. 6, 2012 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery and other surgical applications, today announced plans to report financial results for its second fiscal quarter ended December 31, 2011 on Wednesday, February 8, 2012. The Company has scheduled a conference call that same day, Wednesday, February 8, 2012, at 4:30 pm ET to review the results.

Interested parties can access the conference call by dialing (877) 317-6789 or (412) 317-6789 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company's website at www.misonix.com. 

A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation #10009914. A webcast replay will be available in the Investor Relations section of the Company's website at www.misonix.com for 90 days. 

About Misonix, Inc.
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Company Contact:​

Investor Contacts:

Richard Zaremba​

Robert Blum, Joe Dorame, Joe Diaz

Misonix, Inc.​

Lytham Partners, LLC

631-694-9555​

602-889-9700

invest@misonix.com​

mson@lythampartners.com

www.misonix.com​

www.lythampartners.com

 

SOURCE Misonix, Inc.

Copyright © 2012 PR Newswire Association LLC. All Rights Reserved.

Related Research You May Be Interested In
Advanced Digital Technology Breaking Ground in Light Microscopy
With relatively few progressions in conventional optical microscopy during the past decade, pushing through the physical limitations of these systems has proven to be challenging. Despite this ...Read More
With relatively few progressions in conventional optical microscopy during the past decade, pushing through the physical limitations of these systems has proven to be challenging. Despite this stand-still, engineers have recently been able to develop solutions to some of the limitations in modern microanalysis. Using an integrated design approach, digital microscopes have been developed to overcome many of the shortcomings of conventional optical microscopes. Specifically, in regard to ceramics, one of the major difficulties in observing and analyzing these materials is the complete lack of contrast typically associated with them, especially when viewed through a traditional optical microscope. However, by using the advanced features of fully-integrated digital microscopes, coupled with highresolution zoom lenses and digital camera technology, users can now image samples that were previously relegated to the realm of an SEM.

By: KEYENCE CORP | Published: 6/20/2011
Comparing Miniature DC Motors and Gearboxes from Multiple Vendors
Unlike their fractional and integral horsepower cousins that can be
“Rated” using norms by such organizations as the National Electrical
Manufacturers Association (NEMA) or the International ...Read More
Unlike their fractional and integral horsepower cousins that can be
“Rated” using norms by such organizations as the National Electrical
Manufacturers Association (NEMA) or the International Electrotechnical
Commission (IEC) there are no such standards for rating small
fractional and sub-fractional horsepower dc and stepper motors.

By: MICROMO | Published: 4/29/2011
ADVERTISEMENT